eFFECTOR Therapeutics To Collaborate With The Northwestern University Division Of Hematology And Oncology On An Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib In Patients With Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) has initiated dosing in a Phase 1 trial evaluating tomivosertib in patients with Acute Myeloid Leukemia (AML). The trial will be conducted at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Tomivosertib is an inhibitor of mitogen-activator protein kinase interacting kinase (MNK) 1 and 2 and blocks phosphorylation of eukaryotic initiation factor 4E (eIF4E).
October 24, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
eFFECTOR Therapeutics has initiated a Phase 1 trial for tomivosertib, a potential treatment for AML. This could potentially lead to a new revenue stream if the trial is successful.
The initiation of the Phase 1 trial for tomivosertib represents a significant step in eFFECTOR Therapeutics' product development pipeline. If the trial is successful, it could potentially lead to a new treatment for AML, opening up a new revenue stream for the company. However, it's important to note that the trial is still in its early stages, and there's no guarantee of success.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100